A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2019
At a glance
- Drugs Ceritinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms ASCEND-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2019 Planned End Date changed from 13 Feb 2019 to 29 Apr 2019.